Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:02:16 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:ONCY - ONCOLYTICS BIOTECH INC - https://www.oncolyticsbiotech.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ONCY - Q0.10.80·0.98760.10.8859+0.04935.91,461.81,1181,8130.82  0.9065  0.821.51  0.325819:55:13Feb 0515 min RT 2¢

Recent Trades - Last 10 of 1813
Time ETExPriceChangeVolume
19:55:13Q0.890.053441
19:50:30Q0.890.0534100
19:32:34Q0.88750.05091
19:21:21Q0.89140.05481
19:19:44Q0.89140.05482
19:14:37Q0.89140.054810
19:06:35Q0.89140.05485
19:02:41Q0.89150.05493
18:48:05Q0.89150.054910
18:37:01Q0.870.033451

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-05 09:26U:ONCYNews ReleaseThe $71 Billion Cancer Shift: Why The FDA Is Speeding Up
2026-02-04 08:50U:ONCYNews ReleaseOncolytics Biotech(TM) Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
2026-01-26 10:14U:ONCYNews ReleaseTHE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack
2026-01-15 16:01U:ONCYNews ReleaseOncolytics Biotech(TM) Announces Results of Special Meeting of Shareholders
2026-01-14 10:40U:ONCYNews ReleaseThe $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
2026-01-14 10:15U:ONCYNews ReleaseTHE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points
2026-01-14 09:00U:ONCYNews ReleaseOncolytics Biotech(TM) Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
2026-01-12 10:14U:ONCYNews ReleaseThe $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
2026-01-12 09:00U:ONCYNews ReleaseOncolytics Biotech(TM) Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
2026-01-09 09:00U:ONCYNews ReleaseOncolytics Biotech(TM) Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
2026-01-08 12:08U:ONCYNews ReleaseThe $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
2026-01-07 12:15U:ONCYNews ReleaseTHE CHOKE POINT: 5 Assets That Control the Bottleneck
2026-01-07 09:00U:ONCYNews ReleaseOncolytics Biotech(TM) Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris
2025-12-16 12:18U:ONCYNews ReleaseCancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
2025-12-16 09:00U:ONCYNews ReleaseOncolytics Biotech(TM) Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
2025-12-15 10:55U:ONCYNews ReleaseTHE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
2025-12-12 10:47U:ONCYNews ReleasePancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
2025-12-12 10:31U:ONCYNews ReleaseGI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
2025-12-09 18:00U:ONCYNews ReleaseOncolytics Biotech(TM) Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada